Two clinical trials found that the incidence of MI in those who use rofecoxib was similar to that in those who use ibuprofen or diclofenac.1,2 The VIGOR study found an increased risk of MI with rofecoxib compared with naproxen.3
Rahme E, Pilote L, LeLorier J. Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain—Reply. Arch Intern Med. 2002;162(22):2641. doi:
Best of JAMA Network 2022
Customize your JAMA Network experience by selecting one or more topics from the list below.